I hesitated while pasting together this Bio-Twitter Year in Review because... Does anyone really want to remember what happened in 2016?
Don't all raise your hands at once; 2016 was a lousy year for biotech investors. It started bad, got worse, perked up, got worse again, rebounded just a little, looked like it was normalizing then tanked -- again.
Still, if we have to look back at the pain, why not have some fun with it? I combed through my Twitter archive to compile a 2016 biotech review in tweets. Month by month, here's how 2016 went -- for you and for me.
You know a bad year is coming when your beloved dog dies right after New Year's Day.
Another bad omen for 2016: A news-free start to the J.P. Morgan Healthcare conference.
Biotech stocks cratered...
By the end of January, there was nowhere for investors to hide...
No, dumbass, four more years of Trump!
The only good news I had in 2016.
We were so hopeful, but we're still waiting...
Taking out the trash.
My new best friend.
Valeant (VRX) was a dumpster fire.
Yes, Q1 was bad.
THE FDA adcomm of 2016.
The outcome looked bleak, but...
There was this....
M&A in May! (Just not enough of it.)
The wait continued.
Anyone want to take back their choice?
The biotech circle of life.
The year started bad, and never really stopped being bad.
Drug pricing was the issue that never went away in 2016.
And there were gifs...
It was a great ride.
We were still waiting...
Medivation (MDVN) delivered.
Finally! But the arguments and doubts followed fast.
We made fun of sell-side analysts a lot in 2016. Mostly, they deserved it.
Ariad Pharma (ARIA) does it wrong.
We can praise the sell-side, too.
The brief Trump Bump.
And on the same day!
But the beta-amyloid hypothesis lives on...
Let's hope 2017 is better than 2016. It could hardly be worse.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.